TAG:
laboratory compliance
Ex-IMPATH Executives Face Criminal Charges
By Robert Michel | From the Volume XII No. 6 – April 18, 2005 Issue
CEO SUMMARY: With the announcement by Federal prosecutors of criminal and civil actions against a total of seven ex-IMPATH executives, IMPATH becomes the laboratory industry’s worst criminal scandal. Federal prosecutors contend these executives, during their employment at IMPATH, engine…
OIG Releases Opinion On AP Lab Condominiums
By Robert Michel | From the Volume XII No. 1 – January 3, 2005 Issue
CEO SUMMARY: In responding to a request for an advisory opinion, the Office of the Inspector General (OIG) issued an advisory opinion which declares that anatomic pathology (AP) lab condominiums “could potentially generate prohibited remuneration under the anti-kickback statute.” It a…
Analysis of OIG’s Opinion Shows Compliance Shift
By Robert Michel | From the Volume XII No. 1 – January 3, 2005 Issue
CEO SUMMARY: Attorney Richard Cooper believes the latest Advisory Opinion by the Office of the Inspector General (OIG) is consistent with its earlier anti-kickback law pronouncements about situations where a physician is in a position to profit from the patients he/she refers. Cooper also…
LabCorp’s Smith Speaks On New Pathology Trend
By Robert Michel | From the Volume XI No. 11 – August 9, 2004 Issue
CEO SUMMARY: During the past decade, Laboratory Corporation of America’s Brad Smith faced the spear point of evolving Medicare/Medicaid compliance initiatives which changed so many laboratory industry business practices. Smith believes that business models for in-house anatomic patholog…
Of Congress and the OIG: Speedy Action Ahead?
By Robert Michel | From the Volume XI No. 11 – August 9, 2004 Issue
CEO SUMMARY: During the short life of AP laboratory condominium complexes, they have attracted the interest of both an influential Senator and the Office of the Inspector General (OIG). Last month, Senator Charles E. Grassley sent a letter to the OIG requesting that it investigate the AP …
UroCor’s Sales Tactics Violated Medicare Laws
By Robert Michel | From the Volume XI No. 10 – July 19, 2004 Issue
CEO SUMMARY: By issuing a multi-count criminal indictment against three former UroCor executives, one federal attorney is creating new legal precedents for the laboratory industry. The criminal charges accuse UroCor of inducing physicians through such gambits as deeply-discounted pricing …
Ex-UroCor Execs Face Criminal Indictments
By Robert Michel | From the Volume XI No. 10 – July 19, 2004 Issue
CEO SUMMARY: Criminal charges filed against ex-UroCor executives center around several marketing practices that have much in common with marketing strategies used by many lab- oratories today. These include discounted pricing for non-Medicare specimens, offering to waive charges to payers…
2003’s Big Lab Stories Reflect Health Trends
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: At a minimum, 2003 proved to be a year of relative stability for the laboratory industry, as demonstrated by THE DARK REPORT’S “Ten Biggest Lab Stories of 2003.” The year was free of industry-wide crises and scan- dals. That allowed most laboratory administrators and pa…
Doc “Bill-Back” Policy Rewritten at LabCorp
By Robert Michel | From the Volume X No. 8 – June 16, 2003 Issue
CEO SUMMARY: Laboratory compliance continues to evolve. In response to changes it sees in the lab marketplace, Laboratory Corporation of America instituted a fundamental change in its policy toward billing back physicians who fail to provide documentation necessary for the lab to successf…
Medicare “Bill Back” Policies Vary By Lab
By Robert Michel | From the Volume X No. 4 – March 24, 2003 Issue
CEO SUMMARY: When it comes to the subject of Medicare medical necessity, the classic “compliance conundrum” is again at work. Laboratories with conservative, strict compliance policies believe they are at a disadvantage at retaining physician-clients and winning new accounts when comp…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized